

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

APEC, An A₂-Selective Adenosine Agonist, is a More Potent Locomotor Depressant Than N⁶-Cyclohexyladenosine

Kenneth A. Jacobson^a; Olga Nikodijevic^a; David de la Cruz^a; John W. Daly^a

^a Laboratory of Bioorganic Chemistry, National Inst. of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD

To cite this Article Jacobson, Kenneth A. , Nikodijevic, Olga , de la Cruz, David and Daly, John W.(1991) 'APEC, An A₂-Selective Adenosine Agonist, is a More Potent Locomotor Depressant Than N⁶-Cyclohexyladenosine', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 5, 1211 – 1212

To link to this Article: DOI: 10.1080/07328319108047279

URL: <http://dx.doi.org/10.1080/07328319108047279>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

APEC, AN A₂-SELECTIVE ADENOSINE AGONIST, IS A MORE POTENT LOCOMOTOR
DEPRESSANT THAN N⁶-CYCLOHEXYLADENOSINE

Kenneth A. Jacobson,* Olga Nikodijevic, David de la Cruz, and John W. Daly

Laboratory of Bioorganic Chemistry, National Inst. of Diabetes, Digestive, and Kidney Diseases,
National Institutes of Health, Bethesda, MD 20892.

Abstract: The locomotor depressant effects of APEC are due to activation of central A₂ adenosine receptors, while the depressant effects of NECA are dependent primarily on A₁-receptor activation. A variety of potent A₁-antagonists, including conjugates of the XAC, were screened as antagonists; 2-thio-CPX and CPT reversed effects of CHA, but not of APEC.

Adenosine agonists, such as the A₁-selective CHA (N⁶-cyclohexyladenosine) and the non-selective NECA (5'-N-ethylcarboxamidoadenosine) acting via a central mechanism, cause a dramatic depression of locomotor activity in mice. This depression is effectively reversed by non-selective adenosine antagonists, such as caffeine and theophylline, but not by the peripherally acting sulfo-xanthines.¹ An amine-functionalized congener, APEC, 2-[(2-aminoethylamino)-carbonyl-ethylphenylethylamino]-5'-N-ethylcarboxamidoadenosine, a derivative of CGS21680,² is a potent, centrally active locomotor depressant in mice,³ and its *in vitro* and *in vivo* pharmacology is consistent with A₂-selectivity.

Drugs were administered i.p. in a saline/emulphor mixture (4:1), 10 min before monitoring, in a computerized activity monitor (Digiscan® animal activity monitor, Omnitech Electronics, Columbus OH). Horizontal activity and total distance traveled were studied.³

From dose response curves for horizontal activity, it was found that APEC (ED₅₀ 12 µg/kg) is more potent than CHA (ED₅₀ 60 µg/kg) and less potent than NECA (ED₅₀ 2 µg/kg). The locomotor depression by APEC was reversible by theophylline, but not by the peripheral antagonist 8-p-sulfophenyltheophylline (8-PST), suggesting a central mechanism of action.

In an effort to classify the receptor subtype mediating the depressant effects of APEC, various A₁-selective antagonists (Table) were screened as antagonists of the locomotor effects of adenosine agonists. 8-Cyclopentyl-1,3-dipropyl-2-thioxanthine (2-thio-CPX, 480-fold A₁-




TABLE: Locomotor activity in mice injected with CHA (1 μ mol/kg) alone or followed by a xanthine (10 mg/kg) after 10 min.³ Horizontal activity and total distance travelled are expressed as counts per 30 min, with percent change from control in parentheses. R_8 is given for each xanthine.

CHA + xanthine	n	HA	T.D.
control (no drug)	22	6315 (0%)	3344(0%)
CHA alone	6	803 (\downarrow 87 \pm 19%)	210 (\downarrow 94 \pm 51%)
H ($R_1 = R_2 = CH_3$)	15	7341 (\uparrow 16 \pm 2%)	6732(\uparrow 101 \pm 20%)
cyclopentyl ($R_1 = R_2 = CH_3$, X=S)	11	2503 (\downarrow 60 \pm 10%)	1971 (\downarrow 41 \pm 10%)
cyclopentyl (X=S) = 2-thio-CPX	11	5448 (\downarrow 14 \pm 2%)	4530 (\uparrow 35 \pm 9%)
ϕ -OCH ₂ COOH = XCC	8	2872 (\downarrow 55 \pm 11%)	1839 (\downarrow 45 \pm 15%)
ϕ -OCH ₂ CONH(CH ₂) ₂ OH	14	1901 (\downarrow 70 \pm 14%)	1081 (\downarrow 68 \pm 22%)
ϕ -OCH ₂ CONH(CH ₂) ₂ NH-----H = XAC	11	5729 (\downarrow 9 \pm 3.5%)	4374 (\uparrow 31 \pm 10%)
" -----COCH ₂ ϕ -NH ₂ = PAPA-XAC	12	4812 (\downarrow 24 \pm 4%)	4018 (\uparrow 20 \pm 7%)
" -----CSNH ϕ -F ₅	8	3322 (\downarrow 47 \pm 15%)	1648 (\downarrow 51 \pm 20%)
" -----COCH ₂ NH) ₂ -Cbz	6	2470 (\downarrow 61 \pm 7%)	1119 (\downarrow 67 \pm 9%)

selective in binding assays)⁴ was found to be active centrally, as an antagonist of CHA (1 μ mol/kg). Against APEC at the ED₅₀, neither 2-thio-CPX nor the A₁-selective antagonist 8-cyclopentyltheophylline (CPT)⁵ influenced locomotor depression. This indicated that APEC acts in vivo through A₂-adenosine receptors. Also, CPT was found to completely reverse the locomotor effects of NECA at the ED₅₀, suggesting that the action of NECA is primarily through A₁-adenosine receptors.

REFERENCES

- Seale, T.W.;Abla, K.A.;Shamim, M.T.;Carney, J.M.;Daly, J.W. *Life Sciences* **1988**, *43*,1671.
- Hutchison,A.J.;Webb,R.L.;Oei,H.H.;Ghai,G.R.;Williams,M. *J. Pharm. Exp. Ther.***1989**,*251*,47.
- Nikodijevic, O.; Daly, J.W.; Jacobson, K.A., *FEBS Letters*, **1990**, *261*, 67.
- Jacobson, K.A.;Kiriassil, L.;Barone, S.;Bradbury, B.J.;Kammula, U.;Campagne, J.M.;Secunda, S.;Daly, J.W.;Pfleiderer, W. *J. Med. Chem.* **1989**, *32*, 1873.
- Bruns, R.F.;Davis, R.E.;Ninteman, F.W.;Poschel, B.P.H.;Wiley, J.N.;Heffner, T.G. in: *Physiology and Pharmacology of Adenosine and Adenine Nucleotides* (Paton, D.M. ed) , pp. 39-49, Taylor and Francis, London, **1988**, pp. 39-49.